Furthermore, CBP/β-catenin antagonism with ICG-001 was not toxic to T cells in vitro or in vivo, providing important insights for the advancement of CAR T cell therapy combined with CBP/β-catenin antagonism for the treatment for brain tumors (Supplementary Figure 6). Here, CREBBP is linked to brain neoplasm.